Experimental studies on preventive effects of API₀₁₃₄ on vessel reocclusion after thrombolysis

Abstract

24 model rabbits with femoral arterial thrombosis were divided into two grocps: the treatment group consisting of 12 rabbits which received API₀₁₃₄. and the control group composed of another 12 rabbits. 2 hours after recanalization by urokinase thrombolysis, reocilusion occurred only in 1/12 vessel (8%) with incomplete occlusion in the treated group, but in 8/12 (67%) with complete occlusion in the control group as assessed by angiograsphy. Pathological examination of specimen taken 24 hours after thrombolysis showed that 6/12 (50%) of the treated group gave the evidence of thrombus occlusion, and milder intimai injury and less adhered blood cells than in the control group, 83% of which had thrombus occlusion. In comparision with the control group, the function of platelet in the treated group demonstrated lower platelet aggregation rate (PAgR) and plasma thromboxane A₂ (TXA₂) level, higher prostacyclin (PGI₂) and plasminogen activator (PA) activity as well as lower plasminogen activator inhibitor (PAI) activity. From the above it may be concluded that the preventive effect of API₀₁₃₄ on reocclusion might be due to inhibition of platelets aggregation and promotion of fibrinolysis.

Keywords

API₀₁₃₄ / rabbit / thrombolysis / reocclusion

References

[1] JohnsJ A, GoldH K., LeinbachR C, et al.. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. Circulation., 1988, 78(3): 546-546

[2] BeckerR C. Recurrent myocardial ischemia following thrombolytic therapy: guideline for practicing clinicians. Am Heart J, 1992, 124(1): 183-183

[3] SherryS, MarderV J. Thrombosis, fibrinolysis, and thrombolytic therapy: A perspective. Prog cardiocasc Dis, 1991, 34(1): 89-89

[4] CollenD, LijnenH R, GoldH K. Towards better thrombolytic therapy. Prog Cardiovasc Dis, 1991, 34(1): 101-101

[5] GoldH K, YasudaT., FallonJ T, et al.. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: Prevention by a maintenance infusion. Circulation, 1986, 73(2): 347-347

[6] GolinoP, RosolowskyR, YacS K, et al.. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. J Clin Invest., 1990, 86(4): 1095-1095

[7] ZhaoHuayue. Fang Weiyi. Antithrombotic effects of andrographis paniculatain nees in previnting myocardial infarction. Chinese Medical Journal, 1990, 104(6): 770-770

[8] YasudaT, GoldH K, FallonJ T, et al.. Monoclonal antibody against the. platelet GP 11b/IIIa receptor prevents coronary artery reocclution after reperfusion with recombinant tissue-type plasminogen activatin in dogs. J Clin Invest., 1988, 81(4): 1284-1284

[9] SakamotoT, YasueH, OgawaH. Association of patency of the infarct related coronary artory with plasma levels of plasminogen activator inhibitor activity in acute myocardial infarction. Am J Cardio, 1992, 70(2): 280-280